Welcome to our dedicated page for Ashland news (Ticker: ASH), a resource for investors and traders seeking the latest updates and insights on Ashland stock.
Ashland Inc. (NYSE: ASH) is a global leader in specialty chemicals and advanced additives serving industries from pharmaceuticals to sustainable construction. This page provides investors and professionals with essential updates on corporate developments, financial results, and market innovations.
Discover official press releases alongside curated analysis of Ashland's strategic initiatives in life sciences, personal care ingredients, and industrial solutions. Our repository includes updates on product launches, sustainability efforts, and operational milestones that shape the company's trajectory.
Key content categories include quarterly earnings reports, merger and acquisition activity, leadership changes, and technological breakthroughs in specialty chemicals. All materials are sourced from verified channels to ensure accuracy and relevance for decision-makers.
Bookmark this page for streamlined access to Ashland's evolving story. Check regularly for new developments that demonstrate the company's commitment to solving complex material science challenges through innovation.
Ashland Inc. (NYSE: ASH) appoints Ashish K. Kulkarni, CEO of Kebotix, to its Board of Directors. Kulkarni brings vast experience from leading companies, enhancing innovation, growth, and profitability. The Board expands to 11 members with his addition.
Ashland Inc. (ASH) board of directors has approved a quarterly dividend of $0.405 per share, marking a five percent increase from the prior quarter. The dividend will be paid on June 15, 2024, to stockholders on record as of June 1, 2024. As of April 30, 2024, there were 50,128,349 shares of Ashland common stock outstanding.
Turnspire Capital Partners has announced the acquisition of the nutraceuticals business of Ashland Inc. The acquisition includes Ashland Nutraceuticals, a leading provider of nutrition ingredients and custom formulation services for the nutrition market. Ashland Nutraceuticals has approximately 500 employees across four production facilities in the US and Mexico. The transaction is expected to be completed in the third quarter of 2024.
Ashland Inc. (NYSE: ASH) has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners The transaction is set to close in the third quarter of 2024. Ashland's nutraceuticals business offers active ingredients and formulation aids to nutritional product companies, alongside custom formulation and contract manufacturing services. The deal highlights the business's strong portfolio and capabilities.
Ashland Inc. (NYSE: ASH) reported financial results for the second quarter of fiscal year 2024, with sales at $575 million, down five percent from the prior-year quarter. Net income reached $120 million, or $2.39 per diluted share. Adjusted EBITDA was $126 million, and cash flows from operating activities were $54 million. The company's outlook for the third quarter and full-year fiscal 2024 shows an optimistic perspective on the demand normalization in key segments like Personal Care and Specialty Additives.
FAQ
What is the current stock price of Ashland (ASH)?
What is the market cap of Ashland (ASH)?
